Urelle

Selected form

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urelle

What is Urelle? Overview and Quick Facts

Urelle is a prescription, fixed-dose combination (FDC) medication administered as an oral tablet, designed for symptomatic relief related to urinary tract irritation. Its efficacy stems from a multimodal action, combining five distinct active compounds into a single preparation.

Property	Description
Active Ingredients	Hyoscyamine Sulfate, Methenamine, Methylene Blue, Phenyl Salicylate, Monobasic Sodium Phosphate Monohydrate
Form	Oral tablet (typically film-coated)
Pharmacological Class	Urinary Antispasmodic, Urinary Antiseptic, Analgesic Combination
Common Use	Symptomatic relief of pain, burning, urgency, and spasm associated with urinary irritation
Origin	Synthetic chemical compounds

Composition and Classification

Urelle is classified as a multimodal drug due to its complex composition, which is necessary to address various aspects of urinary discomfort. The core actions are defined by its components: the Hyoscyamine Sulfate provides an antispasmodic (smooth muscle relaxing) effect, while Methenamine acts as a precursor to a localized antiseptic. This type of combination product is clinically recognized for managing both the involuntary muscle tension and the potential microbial contribution to symptoms in the urinary tract.

General Purpose and Differentiation

The general purpose of Urelle is to provide integrated symptomatic relief by targeting multiple sources of discomfort simultaneously. The formulation includes Phenyl Salicylate for its mild analgesic properties and Monobasic Sodium Phosphate Monohydrate to maintain the necessary acidic urinary environment for the Methenamine component to function optimally. This strategic design, which combines an anticholinergic, an antiseptic precursor, an analgesic, and a urinary acidifier, differentiates it from single-agent relief products. The final result is a combined action that helps mitigate disruptive symptoms, such as the frequent and painful urinary urgency often experienced during irritation episodes, by calming irritated tissue and reducing muscle tension.

What side effects are possible with Urelle?

Possible Side Effects and Safety Information

The official safety profile for this combination medicine primarily documents adverse reactions stemming from the hyoscyamine (anticholinergic) component, and specific high-level safety constraints related to the methylene blue ingredient.

Commonly expected, non-serious adverse reactions listed in regulatory documents involve the Gastrointestinal and Nervous Systems, and typically include dry mouth, nausea, vomiting, dizziness, and drowsiness. An expected physiological outcome is that the urine, and sometimes the stools, will turn a blue or blue-green color due to the excretion of methylene blue.

Category	Documented Adverse Reactions/Safety Notes
Serious Adverse Reactions	Risks include the development of Serotonin Syndrome if taken with certain serotonergic psychiatric medications, as documented in the warning section. Signs of severe allergic reaction (such as swelling or trouble breathing) are listed as rare but clinically significant.
Discontinuation Criteria	Regulatory labeling specifies that the occurrence of certain symptoms, namely rapid pulse, blurring of vision, or severe dizziness, requires immediate cessation of the medication.
Population Constraints	The drug is not recommended for use in children six years of age or younger. Caution is advised for older adults (geriatric), who may be more susceptible to effects like confusion, excitement, or drowsiness. The medication is classified as FDA Pregnancy Category C, and components are known to be excreted in breast milk.
Exposure Pattern	Safety information notes that no studies have been established to determine the safety of prolonged use in humans.

This official safety structure emphasizes patient monitoring for key anticholinergic effects and defines clear boundaries for discontinuation, while also formally documenting the expected urine discoloration.

Overdose and Emergency Response

The official regulatory description of overdose for Urelle is defined by the toxicological profiles of its components, primarily the anticholinergic effects and the risk of severe central nervous system (CNS) toxicity.

Documented clinical manifestations of an overdose include signs such as pronounced CNS stimulation, headache, nausea, and specific anticholinergic symptoms like dryness of the mouth, blurred vision, dizziness, and dilated pupils (mydriasis). A rapid pulse (tachycardia) is also a documented outcome that requires immediate discontinuation of the medication.

Of heightened concern is the severe CNS toxicity risk linked to the Methylene Blue component, which may manifest as Serotonin Syndrome. Symptoms requiring urgent medical attention include confusion, hyperactivity, shivering, and high fever. Regulatory labeling explicitly mandates that in the event of suspected accidental overdose, professional assistance or the Poison Control Center must be contacted immediately.

Management procedures documented in official sources include immediate gastric lavage and symptomatic treatment for fever, such as tepid water sponge baths. For the treatment of severe anticholinergic manifestations, the administration of Physostigmine (0.5 to 2 mg intravenously) is mentioned as a specific measure. Regulatory documents note that infants and young children are particularly susceptible to the toxic effects of the belladonna alkaloid component, and elderly patients may show symptoms resembling overdose, such as agitation or confusion, even at usual doses.

Therapeutic Uses of Urelle

What Urelle Treats: Main Uses and Benefits

The primary goal of Urelle is to provide supportive symptomatic relief by managing distressing symptoms related to inflammatory or irritative states of the urinary tract. It is applied across domains where additional symptomatic support is needed, providing support that may assist patients during episodes of heightened discomfort.

The medication is commonly used to help with symptoms in conditions characterized by periods of heightened symptoms, including those associated with lower urinary tract infections (UTIs) and irritation following urological procedures or surgery. This is relevant for managing symptom clusters that may become intense, specifically painful urination (dysuria), bladder spasms, urgency, and frequency. The combination generally assists with managing physical discomfort in conditions associated with irritative states.

The treatment contributes to supporting patients during episodes of heightened symptoms. It is applied during phases of increased distress or discomfort, providing support that contributes to easing the symptom load.

Quick Fact: Relief for Urinary Spasms and Pain The combination is considered relevant for easing symptoms of increased neurological or muscular activity and localized physical discomfort in the urinary tract.

Regulatory References

DailyMed NIH Urelle Label

Eligibility and Restrictions for Use

Urelle is a prescription medication whose use is strictly governed by patient eligibility and regulatory contraindications.

Contraindications (Must Not Use)

Use of Urelle is prohibited for individuals with the following conditions or characteristics:

Hypersensitivity or Allergy to any of the five active ingredients (hyoscyamine, methenamine, methylene blue, phenyl salicylate, sodium biphosphate), belladonna alkaloids, or salicylates.
Specific Medical Conditions including glaucoma, myasthenia gravis, gastrointestinal tract obstructive disease, and acute urinary retention/obstructive uropathy (e.g., due to an enlarged prostate).
Concomitant use with certain serotonergic psychiatric medications, due to the risk of a serious drug interaction.
Severe organ impairment, specifically severe liver disease (hepatic impairment) and renal dysfunction (kidney impairment).

Eligibility Restrictions and Special Populations

Population/Condition	Eligibility Status/Consideration
Children 6 years and younger	Not recommended; safety and efficacy are not established in this age group.
Older Adults (65+)	Use with caution due to increased sensitivity to side effects like confusion, dizziness, and urinary issues.
Pregnancy	Not recommended from 20 weeks gestation until delivery due to potential fetal risk from the salicylate component.
Lactation (Breastfeeding)	Not recommended as the medication may pass into breast milk and potentially harm the infant.

Patients with cardiac conditions (e.g., arrhythmias, congestive heart failure) must use this medicine only after careful risk-benefit consideration by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation outlines specific interaction constraints for Urelle due to its fixed-dose combination of five active compounds. Interactions are primarily classified based on inhibition of drug-metabolizing enzymes, additive pharmacodynamic effects, and dependence on urinary pH.

Formally Contraindicated Combinations

Co-administration with the following drug classes is officially prohibited:

Serotonergic Agents (e.g., SSRIs, MAOIs): Contraindicated due to the Methylene Blue component's inhibition of Monoamine Oxidase A, risking Serotonin Syndrome.
Sulfonamides and Urine Alkalinizing Agents: Contraindicated because alkaline agents inactivate the Methenamine component, while sulfonamides can form an insoluble precipitate.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Officially Documented Effect	Constraint Focus
Enzyme Inhibition	Methylene Blue is a potent inhibitor of CYP2D6, increasing the systemic exposure (plasma concentration) of co-administered CYP2D6 substrates.	Exposure Modification
Pharmacodynamic	Additive adverse effects occur with other Anticholinergic Agents or CNS Depressants (including alcohol).	Additive Effects

Timing and Population Constraints

The Hyoscyamine component, by altering gastrointestinal motility, requires that Antacids and anti-diarrhea adsorbents be administered at least one hour before or after Urelle. Interaction-related adverse effects, particularly those involving the central nervous system or anticholinergic activity, may be more pronounced in elderly patients.

Mechanism of Action

Modulating Peripheral Autonomic Control

This domain relies on Hyoscyamine, a competitive antagonist that primarily targets peripheral muscarinic acetylcholine receptors on detrusor smooth muscle. By blocking cholinergic stimulation, the mechanism modifies parasympathetic signaling dynamics, modulating smooth muscle tone and decreasing spontaneous contractile activity.

pH-Dependent Localized Antiseptic Cascade

This mechanism integrates Methenamine and Monobasic Sodium Phosphate Monohydrate. The phosphate component maintains the necessary acidic environment ( pH < 5.5) for Methenamine to undergo acid-catalyzed hydrolysis and generate Formaldehyde. This chemical cascade initiates the denaturing and cross-linking of microbial proteins and nucleic acids directly within the urinary fluid.

Attenuating Peripheral Nociceptive Signals

This domain is mediated by the active metabolite of Phenyl Salicylate, which functions as a non-selective inhibitor of Cyclooxygenase (COX) enzymes. By suppressing this key enzymatic step in the Arachidonic Acid Cascade, the synthesis of prostaglandins is reduced. This modification lowers the activity threshold for peripheral nerve sensitization.

Dosage and Administration Information

Official Administration Guidelines for Urelle

Urelle is a prescription medication administered exclusively via the oral route as a fixed-dose tablet or capsule. The usage pattern is standardized across adults, focusing on maintaining stable administration levels throughout the day.

Dosage and Frequency

The standard dosing regimen for adults involves taking one tablet or capsule per administration. This dose is scheduled four times per day (QID), and the total daily dose should not exceed four tablets. Doses are typically spaced approximately six hours apart to adhere to this divided daily schedule. If a dose is missed, patients are instructed to take it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely to prevent taking a double amount.

Administration Conditions

Proper use of Urelle requires specific contextual steps. Administration must be accompanied by the consumption of liberal fluids; this fluid intake is a stated requirement for appropriate use. The medication can generally be taken without reference to food, such as with or without a meal. A known procedural consequence of taking Urelle is that the presence of Methylene Blue in the formulation will commonly cause the urine to appear blue or blue-green.

Population-Specific Use

Official labeling contains specific constraints regarding the use of Urelle in pediatric patients. The medication is not recommended for use in children 6 years of age and younger. For children older than 7 years, the dosage regimen is not standardized and must be determined individually by a physician.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Urelle

Evidence for use in Irritative Voiding Symptoms

Studies conducted research exploring how symptoms change over time related to irritative voiding. These studies typically involved populations experiencing uncomfortable urinary symptoms like urgency and increased frequency. The main focus was on patient-reported outcomes describing perceived discomfort and how symptoms evolved in the observed populations during the short study periods.

Findings describe patterns observed in the studies related to measurements taken of patient-reported outcomes describing perceived discomfort and frequency of urination. However, findings were sometimes mixed across different research settings, and the short-term nature of the research means that evidence remains limited regarding sustained measurements over longer periods.

Evidence for use in Urinary Symptoms Associated with Lower Urinary Tract Infections (UTIs)

This part outlines the research evidence, including the designs of the studies, that focused on characterizing reported symptom changes (such as discomfort and hypermotility) when this product was used alongside or following treatment for lower urinary tract infections.

Studies monitored temporary physiological imbalance and discomfort applied in research contexts involving fluctuating or unstable symptoms linked to irritative states often associated with lower UTIs. Data show patterns related to measurements taken in outcomes related to physical discomfort during the period of increased symptom activity.

What is still uncertain is how these findings would apply to a population with chronic or recurring infections, as the studies mainly focused on the temporary, acute period. Results apply only to the populations studied, and certainty remains low regarding measurements beyond the treatment of the underlying infection.

Evidence for use in Urinary Symptoms Caused by Diagnostic or Surgical Procedures

Research explored short-term symptom changes in populations following certain medical interventions like cystoscopy or bladder catheterization. These are conditions associated with acute or disruptive episodes and often involve periods of heightened symptoms. Research describes studies examining symptom intensity or variability caused by temporary trauma or irritation.

Studies report how symptoms evolved in the observed populations immediately following the procedure. Research provides insight into short-term measurements in pain and urgency. The studies contribute to the broader evidence landscape related to post-procedural recovery.

What is still Uncertain about Urelle

The evidence highlights what is known and what is still uncertain about this product. Sample sizes were often modest in the initial research. This means that findings describe group patterns, not personal measurements, and research does not determine whether an individual will respond similarly.

Key uncertainties center on long-term measurements of change, which are not fully established. There is also limited information regarding measurements in certain special populations, and comparative evidence is lacking to directly compare this product with other interventions for the same indications. Findings were sometimes mixed depending on the specific method used to measure symptoms.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Urelle (FAQ)

Q: What is Urelle and what is it approved for?

A: Urelle is a prescription medication approved by the FDA for treating symptoms associated with urinary tract infections (UTIs), bladder spasms, and inflammation of the lower urinary tract. It contains a combination of ingredients to help address pain and discomfort in the urinary system.

Q: What are the main ingredients in Urelle?

A: Urelle contains a combination of active ingredients. These typically include methenamine and sodium phosphate monobasic, which may help maintain a urinary environment unfavorable for bacterial growth, along with phenyl salicylate and methylene blue for analgesic and antiseptic properties.

Q: How quickly does Urelle start to work?

A: The analgesic components of Urelle may begin to help with pain and discomfort relatively quickly. However, the full intended effect of the medication, particularly in managing the urinary environment, is typically based on consistent use as prescribed by a healthcare provider.

Q: What should I discuss with my doctor before starting Urelle?

A: Before starting Urelle, it is important to discuss your complete medical history with your healthcare provider. This discussion should cover:

Existing Medical Conditions: Such as kidney disease, glaucoma, or certain heart conditions.
Current Medications: Including all prescription drugs, over-the-counter medicines, and supplements.
Pregnancy and Breastfeeding: Your provider will discuss the potential considerations of using Urelle while pregnant or breastfeeding.

Q: Can Urelle change the color of my urine?

A: Yes, one of the ingredients in Urelle, methylene blue, is known to cause a harmless blue-green discoloration of the urine. This is a common and expected effect of the medication and does not indicate a health concern. It is important to be aware of this change while taking Urelle.

How should Urelle be stored and disposed of?

Storage and Disposal of Urelle Tablets

Urelle tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in a tight, light resistant container and protected from freezing, excess heat, and moisture.

Handling and Safety

It is mandatory to store Urelle out of the reach of children. The product is supplied in child resistant bottles.

Disposal

For disposal of unused or expired Urelle, patients should consult a healthcare professional for guidance. Official labeling instructs that the medicine should not be kept if it is outdated or no longer needed. General federal guidelines should be followed if a drug take-back program is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

USA

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z